Article
KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes.
Clinical pharmacology and therapeutics - 1 Mar 2010
Yu M, Xu X-J, Yin J-Y, Wu J, Chen X, Gong Z-C, Ren H-Y, Huang Q, Sheng F-F, Zhou H-H, Liu Z-Q
Abstract excerpt
This study showed that the polymorphisms KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) are associated with a heightened risk of developing type 2 diabetes mellitus (T2DM). We also explored the effects of these polymorphisms on the efficacy of repaglinide therapy in Chinese patients with T2DM. A total of 259 patients with T2DM and 188 healthy controls were genotyped. Forty patients with various genotypes were randomly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.